A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess whether LY2216684 12 milligrams (mg) or 18
mg flexible dose once daily is superior to placebo once daily in the adjunctive treatment of
participants with major depressive disorder (MDD) who are partial responders to their
selective serotonin reuptake inhibitor (SSRI) treatment.